Genotype-guided strategy for antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease.

Phase 4

Recruiting

• Conditions: lower extremity arterial disease; Peripheral arterial disease; 10003216

• Registration Number: NL-OMON50838
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 2276

Inclusion Criteria

- age > 16 years
- obtained written informed consent
- indication for monotherapy clopidogrel 75mg once daily
- ankle-brachial index < 0.9 and/or toe brachial index < 0.5
- current or previous symptoms due to insufficient vascularization of one or
two lower extremities, including intermittent claudication, pain at rest and/or
gangrene (Rutherford category 1-6)
- consulting a vascular surgeon for diagnosis, treatment and/or follow-up of
PAD symptoms

Exclusion Criteria

- known CYP2C19*2 and *3 status
- treated with coumarins, Non-vitamin K Oral Anti-Coagulants, unfractionated
heparin, low molecular weight heparins or double antiplatelet therapy for other
indications
- contraindication for clopidogrel, acetylsalicylic acid and/or rivaroxaban
- life expectancy of less than 1 year
- pregnant or breastfeeding women
- unable to give informed consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified